Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GenScript ProBio Extends Drug Development Collaboration with REMB

publication date: Sep 17, 2020

GenScript ProBio, a Nanjing CDMO, agreed to license a bispecific antibody to REMD Bio for an undisclosed target. REMD is a clinical stage San Francisco-Beijing biologics company.  REMD will pay GenScript ProBio service fees, commercialization milestones and royalties. The bispecific antibody is derived from single-domain antibody fused to GenScript's monoclonal antibody (SMAB) platform. In 2019, the two companies formed a collaboration to develop several novel bispecific cancer immunotherapy candidates. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital